Compare Hewlett Packard Enterprise Co (HPE) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs Novo Nordisk A/S — how do they compare? Hewlett Packard Enterprise Co trades at $73.46 (market cap $94.25B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Novo Nordisk A/S for 116 Days on average.
| HPE | NVO | |
|---|---|---|
Market Cap | $94.25B | $165.31B |
Volume | 16,060,854 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $72.12 | $63.98 |
52-Week Low | $20.01 | $35.29 |
Typical Hold Time | 33 Days | 116 Days |
Enterprise Value | $108.28B | $179.56B |
Dividend Yield | 0.8% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE trades at $73.46, up 1.87% today and near its 52-week high, driven by strong AI infrastructure demand. The stock has a bullish technical signal with moving averages supporting the uptrend. Recent earnings beats, including Q2 2026 EPS of $1.11 versus $0.932 expected, highlight operational strength. A $1.2 billion AI server order from Vultr and raised revenue guidance fuel optimism, though valuation ratios like a P/E of 36.6 suggest premium pricing.
Outlook remains positive with AI-driven growth catalysts, but risks include high valuation and competitive pressures. Analyst consensus is mixed with a $70.35 price target, slightly below current levels. Net income margin compression in 2025 to 0.16% warrants monitoring, though 2026 projections show recovery. The stock's momentum hinges on execution of AI orders and margin expansion.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
